Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
8
|
| pubmed:dateCreated |
1990-9-7
|
| pubmed:abstractText |
From August 1985 to November 1989 we conducted a trial of intraperitoneal (IP) carboplatin including a dose-escalation design in 25 women with advanced gynecologic malignancies. All had extensive prior therapy with cisplatin (median cumulative dose, 525 mg/m2). Carboplatin was administered IP in 2 L of 1.5% dextrose with a 4-hour dwell time every 4 weeks for six cycles at a starting dose of 200 mg/m2. Patients with reduced creatinine clearance (30 to 60 cc/min) were escalated more slowly than those with high (greater than 60 cc/min) clearance. Thrombocytopenia was dose-limiting and often more severe in patients with compromised renal function; there was no local drug toxicity. The median time of follow-up is 25 months. Complete responses (CRs) were documented in six of 23 assessable patients (26%) by repeat laparotomy, and an additional 11 patients (48%) had no disease evident by noninvasive restaging. Five of the CRs and six of the patients with no clinically evident disease have relapsed from 3 to 40 months after therapy. Six patients (26%) are alive and free of disease 8 to 47 (median, 20) months after therapy. IP carboplatin is effective against relapsed ovarian cancer, even after prior cisplatin therapy.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Carboplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Creatinine,
http://linkedlifedata.com/resource/pubmed/chemical/Organoplatinum Compounds
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0732-183X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
8
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
1335-41
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:2199620-Adenocarcinoma,
pubmed-meshheading:2199620-Adult,
pubmed-meshheading:2199620-Aged,
pubmed-meshheading:2199620-Antineoplastic Agents,
pubmed-meshheading:2199620-Carboplatin,
pubmed-meshheading:2199620-Cisplatin,
pubmed-meshheading:2199620-Creatinine,
pubmed-meshheading:2199620-Drug Evaluation,
pubmed-meshheading:2199620-Female,
pubmed-meshheading:2199620-Follow-Up Studies,
pubmed-meshheading:2199620-Humans,
pubmed-meshheading:2199620-Infusions, Parenteral,
pubmed-meshheading:2199620-Kidney,
pubmed-meshheading:2199620-Middle Aged,
pubmed-meshheading:2199620-Organoplatinum Compounds,
pubmed-meshheading:2199620-Ovarian Neoplasms,
pubmed-meshheading:2199620-Peritoneal Cavity,
pubmed-meshheading:2199620-Remission Induction,
pubmed-meshheading:2199620-Survival Rate,
pubmed-meshheading:2199620-Thrombocytopenia
|
| pubmed:year |
1990
|
| pubmed:articleTitle |
Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy.
|
| pubmed:affiliation |
Rita and Stanley H. Kaplan Cancer Center, Department of Medicine, New York University Medical Center.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|